Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9007225rdf:typepubmed:Citationlld:pubmed
pubmed-article:9007225lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:9007225lifeskim:mentionsumls-concept:C0019764lld:lifeskim
pubmed-article:9007225lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:9007225lifeskim:mentionsumls-concept:C0882849lld:lifeskim
pubmed-article:9007225lifeskim:mentionsumls-concept:C0205245lld:lifeskim
pubmed-article:9007225lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:9007225lifeskim:mentionsumls-concept:C1413221lld:lifeskim
pubmed-article:9007225lifeskim:mentionsumls-concept:C1439292lld:lifeskim
pubmed-article:9007225lifeskim:mentionsumls-concept:C0205100lld:lifeskim
pubmed-article:9007225lifeskim:mentionsumls-concept:C1705241lld:lifeskim
pubmed-article:9007225lifeskim:mentionsumls-concept:C1705242lld:lifeskim
pubmed-article:9007225pubmed:issue1lld:pubmed
pubmed-article:9007225pubmed:dateCreated1997-5-8lld:pubmed
pubmed-article:9007225pubmed:abstractTextWe have investigated the functional characteristics of peripheral blood-derived CD34+ cells mobilized by a combination of chemotherapy and G-CSF (mobilized peripheral blood-derived [MPB] CD34+ cells). In this study, subpopulations of MPB CD34+ cells have been directly compared in clonal cultures, long-term cultures with bone marrow (BM) stromal cells, and single-cell cultures. MPB CD34+ cells could be subdivided by expression levels of HLA-DR (DR), CD38, CD33 and c-kit antigens. The majority of MPB CD34+ cells expressed DR and CD38 antigens. In contrast, approximately 60% and 20% of the MPB CD34+ cells expressed CD33 and c-kit antigens, respectively. Interestingly, MPB CD34+ cells can be subdivided into three fractions which express high, low or negative levels of c-kit receptor. All types of committed progenitors were observed in populations of CD34+DR+, CD34+DR-, CD34+CD33-, CD34+CD38+ and CD34+ c-kit(low) cells. Colony forming unit-granulocyte/macrophage was highly enriched in the population of CD34+CD33+ cells, whereas BFU-E was highly enriched in the population of CD34+ c-kit(high) cells. In the population of CD34+CD38- cells, however, a few myeloid progenitors were detected. In addition, limiting dilution analyses clearly showed that the long-term culture-initiating cell (LTC-IC) is enriched in the populations of CD34+DR-, CD34+CD33- and CD34+c-kit-(or low) cells, but very few in CD34+ c-kit(high) cells, and that CD38 antigen is not a useful marker for the enrichment of LTC-IC derived from MPB CD34+ cells. Moreover, single cell clone sorting experiments clearly demonstrated the functional differences between CD34+CD38+ and CD34+CD38- cells as well as CD34+ cells expressing different levels of c-kit receptor. Our results suggest that an immunophenotype of LTC-IC is different between BM-, cord blood- and MPB-derived CD34+ cells and that primitive and committed progenitors existing in these sources may be functionally different.lld:pubmed
pubmed-article:9007225pubmed:languageenglld:pubmed
pubmed-article:9007225pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:citationSubsetIMlld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9007225pubmed:statusMEDLINElld:pubmed
pubmed-article:9007225pubmed:issn1066-5099lld:pubmed
pubmed-article:9007225pubmed:authorpubmed-author:AbeTTlld:pubmed
pubmed-article:9007225pubmed:authorpubmed-author:KimuraTTlld:pubmed
pubmed-article:9007225pubmed:authorpubmed-author:MoriK JKJlld:pubmed
pubmed-article:9007225pubmed:authorpubmed-author:SakabeHHlld:pubmed
pubmed-article:9007225pubmed:authorpubmed-author:SonodaYYlld:pubmed
pubmed-article:9007225pubmed:authorpubmed-author:TanimukaiSSlld:pubmed
pubmed-article:9007225pubmed:authorpubmed-author:OhmizonoYYlld:pubmed
pubmed-article:9007225pubmed:issnTypePrintlld:pubmed
pubmed-article:9007225pubmed:volume15lld:pubmed
pubmed-article:9007225pubmed:ownerNLMlld:pubmed
pubmed-article:9007225pubmed:authorsCompleteYlld:pubmed
pubmed-article:9007225pubmed:pagination73-81lld:pubmed
pubmed-article:9007225pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:meshHeadingpubmed-meshheading:9007225-...lld:pubmed
pubmed-article:9007225pubmed:year1997lld:pubmed
pubmed-article:9007225pubmed:articleTitleFunctional differences between subpopulations of mobilized peripheral blood-derived CD34+ cells expressing different levels of HLA-DR, CD33, CD38 and c-kit antigens.lld:pubmed
pubmed-article:9007225pubmed:affiliationSecond Department of Internal Medicine, Shiga University of Medical Science, Japan.lld:pubmed
pubmed-article:9007225pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9007225pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9007225pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed